ADVENTRX ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced financial results for the three and six months ended June 30, 2005. ADVENTRX reported a net loss of $3.3 million, or $0.06 per share, for the second quarter of 2005, compared with a net loss of $1.5 million, or $0.03 per share, for the second quarter of 2004. "In past several months, we have moved significantly closer to our corporate goal of introducing new anticancer and antiviral treatments that improve the performance and safety of existing drugs," said Evan M. Levine, ADVENTRX president and chief executive officer.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1033286XSL_NEWSML_TO_NEWSML_WEB.xml)